KALA BIO (NASDAQ:KALA – Get Free Report) and Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability. Institutional and Insider Ownership 24.0% of KALA […]
/PRNewswire/ The "Global Neurotrophic Keratitis Market (2023-2028) by Route of Administration, Distribution Channel, and Geography, Competitive Analysis,.
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA – Free Report)’s share price was down 4.5% during mid-day trading on Thursday . The stock traded as low as $14.21 and last traded at $14.37. Approximately 68,731 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 693,209 shares. The stock had previously closed […]
Kala Pharmaceuticals, Inc. (NASDAQ:KALA – Free Report) was down 4.5% during trading on Thursday . The stock traded as low as $14.21 and last traded at $14.37. Approximately 68,731 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 693,209 shares. The stock had previously closed at $15.04. Analysts […]